Beijing Biotech Drug Pipeline

Beijing Biotech's portfolio includes 19 registered clinical trials, all initiated since 2008, with 19 currently active. The pipeline is heavily weighted toward early-stage development, with all active trials in Phase 1 (19) or Phase 2 (16). The company's research is focused across two therapeutic areas, with a significant concentration in oncology. Within oncology, Beijing Biotech has 24 active trials, representing 126% of its active programs, indicating some trials may address multiple indications. The leading indications within oncology include breast cancer, HER2+ breast cancer, triple negative breast cancer, glioblastoma, and brain tumor, each with two active trials. No programs have advanced to Phase 3 in any indication. The remaining active trial is in immunology. The portfolio's early-stage focus and concentration in oncology suggest a strategic emphasis on novel targets or approaches within this therapeutic area.